Free press releases distribution network?

More news: Health/Surgery
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Ripe for Innovative, Non-invasive Treatments - The Market Will Almost Double by 2017 Finds Frost & Sullivan - Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market - LifeSciences.Frost.com
Ripe for Innovative, Non-invasive Treatments - The Market Will Almost Double by 2017 Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2014/01/08 - Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market - LifeSciences.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration.

New analysis from Frost & Sullivan's (lifesciences.frost.com) Analysis of the US Retinal Therapeutics Market finds the market earned revenue of $2.45 billion in 2012 and estimates this to almost double to $4.15 billion in 2017.

For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Despite the popularity of VEGF inhibitors in the U.S., issues of patient preference and compliance, the risk of infection, as well as side effects such as floaters, increased intraocular pressure and inflammation of the eye exist," said Frost & Sullivan Life Sciences Senior Industry Analyst Debbie Toscano. "There is also a lack of substantive long term data on the ability of VEGF therapy to prevent visual impairment."

In addition, the rapid uptake of low-cost Avastin, supplied by compounding pharmacies, is challenging the VEGF inhibitors market. Although the U.S. Food and Drug Administration has drawn attention to safety issues with compounding pharmacies, physicians are accustomed to the inherent risks associated with using compounded Avastin, and patients too value the affordability of the drug.

"Regardless of the widespread off-label usage of Avastin for retinal diseases, there is still significant scope for market penetration through innovative formulations and drug delivery methods," pointed out Toscano. "For instance, market participants could roll out add-on therapies which can be combined with any VEGF inhibitor to boost efficacy. New treatments that can be administered orally or topical drops too would revolutionize treatment and garner significant market adoption in place of intravitreal injections."

Analysis of the US Retinal Therapeutics Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related research services include: Analysis of the Global Type 2 Diabetes Therapeutics Market, Global Analysis of MicroRNA Tools and Services Market, Global Pharmaceutical Contract Manufacturing Market, and Breakthroughs in Ophthalmic Devices and Drug Delivery Technologies. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

Analysis of the US Retinal Therapeutics Market / NC77-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Ripe for Innovative, Non-invasive Treatments - The Market Will Almost Double by 2017 Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Jennifer Carson - Frost.com 
210-247-2450 jennifer.carson[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Ultimate Medical Group Announces A New Regenerative Medicine Division

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today